The use of deferoxamine infusions to enhance the response rate to interferon-α treatment of chronic viral hepatitis B

Journal of Viral Hepatitis

Volumn 3, Issue 3, 1996, Pages 129-135

  Bayraktar, Y ^a   Koseoglu, T ^a   Somner, C ^a   Kayhan, B ^a   Temizer, A ^a   Uzunalimoglu, B ^a   De Maria, N ^b   Van Thiel, D H ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Antiviral therapy; Ferritin; Iron; Liver; Seroconversion

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; DEFEROXAMINE; FERRITIN; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; SIDEROPHORE; VIRUS DNA;

ADULT; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHRONIC DISEASE; DEFEROXAMINE; DNA, VIRAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; MALE; SIDEROPHORES;

EID: 0030133437     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1996.tb00003.x     Document Type: Article

References (49)

1. Lambiase L, Davis G. Treatment of chronic hepatitis. Gastroenterol Clin N Am 1992; 21: 659-677.
2. Hoofnagle JH, Jones A. Therapy of chronic viral hepatitis. Past, present and future. Semin Liver Dis 1989; 9: 231-234.
3. Naoumov NV, Thomas MG, Mason AI et al. Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon-alpha treatment. Gastroenterology 1995; 108: 505-514.
4. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763.
5. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon α therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-415.
6. Olynyk JK, Reddy KR, Di Bisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon α therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-1109.
7. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatology 1991; 13: 372-774.
8. Kreeftenberg HG, Kooman BJ, Huizenga JR et al. Measurement of iron in liver biopsies: a comparison of three analytical methods. Clin Chim Acta 1984; 144: 255-262.
9. Sussman HH. Iron in cancer. Pathobiology 1992; 60: 2-9.
10. Halliwell B, Gutteridge JMC. Oxygen toxicity, free radicals, transition metals and disease. Biochem J 1984; 219: 1-14.
11. Brissot P, Bourel M, Henry D et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology 1981; 80: 557-565.
12. Harrison PM. Ferritin: an iron storage molecule. Semin Haematol 1977; 14: 55-70.
13. Sibille JC, Kondo H, Aisen P. Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein. Hepatology 1988; 8: 296-301.
14. Omara Fo, Blakely BR. The effects of iron deficiency and iron overload on cell-mediated immunity in the mouse. Br J Nutr 1994; 72: 899-909.
15. Sherman AR. Zinc, copper and iron nutriture and immunity. J Nutr 1992; 122: 604-609.
16. Shau H, Kim A, Golub SH. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukocyte Biol 1992; 51: 343-349.
17. Santos PC, Falcao RP. Decreased lymphocyte subsets and K-cell activity in iron deficiency anemia. Acta Hematol 1990; 84: 118-121.
18. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990; 11: 127-137.
19. Badylack SF, Simmons A, Turek J et al. Protection from reperfusion injury in the isolated rat heart by post-ischemic deferoxamine and oxypurinol administration. Cardiovasc Res 1987; 21: 500-506.
20. Van Der Kraaij AMM, Van Eijk HG, Koster JF. Prevention of post-ischemic cardiac injury by the orally active iron-chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidol-3. Circulation 1989; 80: 158-164.
21. Kobayashi S, Tadokoro H, Wakida Y et al. Coronary venous retroinfusion of deferoxamine reduces infarct size in pigs. Am Coll Cardiol 1991; 18: 621-627.
22. Caraceni P, Van Thiel DH, Borle AB. Dual effect of deferoxamine on free radical formation and reoxygenation injury in isolated hepatocytes. Am J Physiol 1995; 269: G132-G137.
23. Bonkovsky HL. Iron and the liver. Am J Med Sci 1991; 301: 32-43.
24. Lustbader ED, Hann HL, Blumberg HS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220: 423-425.
25. Senba M, Nakamura T, Itakura T. Statistical analysis of relationship between iron accumulation and hepatitis B surface antigen. Am J Clin Pathol 1985; 84: 340-342.
26. Felton C, Lustbader ED, Merten C et al. Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci USA 1979; 76: 2438-2441.
27. Piperno A, D'Alba R, Roffi L et al. Hepatitis C virus infection in patients with idiopathic hemochromatosis (IH) and porphyria cutanea tarda (PCT). Arch Virol 1992; 4: 215-216.
28. Jaffin BW, Ambinder EP. Hemochromatosis and hepatitis C. Hosp Pract 1991; 26: 50-51.
29. Fargion S, Piperno A, Cappellini MD et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322-1326.
30. Litwin CM, Calderwood SB. Role of iron in regulation of virulence genes. Clin Microbiol Rev 1993; 6: 137-138.
31. Byrd TF, Horwitz MA. Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest 1989; 83: 1457-1465.
32. Borysiewicz LK, Graham S, Sissons JGP. Human natural killer cells lysis of virus-infected cells. Relationship to expression of the transferrin receptor. Eur J Immunol 1986; 16: 405-411.
33. Brock JH. Iron in infection, immunity, inflammation and neoplasia. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. London (UK): WB Saunders Company Ltd 1994: 353-389.
34. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-456.
35. Silliman CC, Peterson VM, Mellman DL et al. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double blind study of the dose-response relationship. J Lab Clin Med 1993; 122: 48-54.
36. Olivieri NF, Berriman AM, Tyler BJ et al. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. Am J Hematol 1992: 41: 61-63.
37. Rocchi E, Cassanelli M, Borghi A et al. Liver iron overload and deferoxamine treatment of porphyria cutanea tarda. Dermatologica 1991; 182: 27-31.
38. Richardson ME, Matthews RN, Allison JF et al. Prevention of heart disease by subcutaneous deferoxamine in patients with thalassemia major. Aust NZ J Med 1993; 23: 656-661.
39. Mehta AM, Engstrom RE Jr, Kreiger AE. Deferoxamine-associated retinopathy after subcutaneous injection. (letter) Am J Ophthalmol 1994; 118: 260-262.
40. Koren G, Kochavi-Atiya Y, Bentur Y et al. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Hemat 1991; 54: 371-375.
41. Olivieri NF, Buncic JR, Chew E et al. Visual and auditory neurotoxicity in patients receiving deferoxamine infusions. N Engl J Med 1986; 314: 869-873.
42. Dusheiko G, DiBisceglie A, Bowyer S et al. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 1985; 5: 556-560.
43. Brook MG, Chan G, Yap I et al. Randomised controlled trial of lymphoblastoid interferon alpha in Europid men with chronic hepatitis B virus interferon. Br Med J 1989; 299: 652-656.
44. Alexander GJM. Loss of HBsAg with interferon therapy in chronic hepatitis virus infection. Lancet 1987; II: 66-68.
45. Saracco G, Mazzella G, Rosina F et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10: 336-341.
46. Bacon RB, Rebholz AE, Fried M et al. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon α. (abstract) Hepatology 1993; 18: 150.
47. Van Thiel DH, Friedlander L, Malloy P et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepato-Gastroenterology (in press).
48. Gupta RC, Mulhotra S, Lehandekar P et al. Influence of low iron diet on the efficacy of interferon therapy in patients with chronic liver disease. Proceedings of IX Bicennial Scientific Meeting, Asian Pacific Association for the Study of the Liver. Kuala Lampur, Malaysia: January 26-29, 1994.
49. Hayashi H, Takikawa T, Nishimura N et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-989.